|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
1989-6-22
|
|
pubmed:abstractText |
A sparteine test was carried out in 14 patients suffering from acute schizophrenic psychoses before and 1-2 times during oral haloperidol treatment in doses of 10-40 mg day-1. In patients classified as extensive metabolisers (sparteine MR less than 20 before treatment), haloperidol treatment resulted in a rise in sparteine MR that correlated with the serum-haloperidol concentration both within and between patients. At the highest serum haloperidol concentrations (60-80 nM) an increase in sparteine MR by a factor 15-50 was seen, but no patients were transformed into phenotypically poor metabolisers. The steady state concentration of haloperidol on the initial standard dose of 10 mg day-1 was the same in one patient classified as a sparteine poor metaboliser (MR = 112) as in eleven patients classified as extensive metabolisers (MR:0.22-1.47).
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/2713222-1223997,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2713222-2863108,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2713222-2874826,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2713222-2894945,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2713222-3567021,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2713222-3588528,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2713222-3709631,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2713222-3756067,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2713222-3769385,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2713222-3780830,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2713222-4281877,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2713222-6141510,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2713222-6220203,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2713222-6812109,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2713222-6827912,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2713222-7053300,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2713222-7442467
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
0306-5251
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
27
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
272-5
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
|
|
pubmed:year |
1989
|
|
pubmed:articleTitle |
Substantial rise in sparteine metabolic ratio during haloperidol treatment.
|
|
pubmed:affiliation |
Centre Psychiatrique Esquirol, University Hospital Center of Caen, France.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
